


Sutacimig - A Novel Prophylactic Treatment for Glanzmann Thrombasthenia: Interim Analysis of a Phase 1/2 Study

Suthesh Sivapalaratnam^{1,2}, Laurent Frenzel³, Frederico Xavier⁴, Peter Verhamme⁵, Roger Schutgens⁶, Paul Saultier⁷, Andrea Artoni⁸, Catherine Rea⁹, Ashley Gosnell⁹, Joseph Vogel⁹, Pruthvi Nagilla⁹, Tara Parsons⁹, Jigar Amin⁹, Ulrike Lorch⁸, Matej Goricar⁸, Michael Kelly⁹

¹Queen Mary University of London, ²Barts Health NHS Trust, ³Necker Hospital, ⁴University of Pittsburgh, ⁵KU Leuven, ⁶University Medical Centre Utrecht, ⁷APHM, Hospital de la Timone, ⁸IRCCS Ca' Granda Maggiore Hospital, ⁸Richmond Pharmacology, ⁹Hemab Therapeutics. Phase I was conducted at Richmond Pharmacology Ltd (RPL)

Contact details

Suthesh Sivapalaratnam
s.sivapalaratnam@nhs.net



In compliance with COI policy, ISTH requires the following disclosures to the session audience:

Shareholder	No relevant conflicts of interest to declare
Grant / Research Support	Sanofi, CSL Behring, Pfizer
Consultant	Guidepoint, CSL Behring, Hemab Therapeutics
Speaker bureau	Sanofi, CSL Behring, Chugai/Roche, Takeda
Patients for drugs or devices	No relevant conflicts of interest to declare
Other	No relevant conflicts of interest to declare

Glanzmann Thrombasthenia: platelet aggregation defect causing frequent bleeding events

Severe platelet function disorder



Characterized by deficient or dysfunctional GPIIb/IIIa expression on platelets impairing platelet aggregation and platelet-fibrinogen binding during primary hemostasis

Frequent bleeding events from low-volume bleeding to life-threatening hemorrhages¹⁻²



88% of patients bleed weekly

> 50% bleed 3 x per week

80% miss school or work

No approved therapies for primary prophylaxis




30% develop alloimmunization to platelets

Current treatment options are limited by short half-lives, high costs, and complications with IV administration

Frequent bleeding events accumulate to create a significant clinical impact, including iron deficiency, and impaired quality of life.

Sutacimig Binds FVIIa and TLT-1 to Enhance Thrombin Generation



Multiple Ascending Dose Evaluation with Long-term Extension

Enrollment complete

Study objectives

Primary:

- Safety/tolerability
- PK/PD

Secondary:

- Efficacy

Study population

- Confirmed GT diagnosis
- History of bleeding requiring treatment
- Adults 18–67 years

Safety population


- N=34

Efficacy population

- N=33*

Results of SAD portion previously presented^

- N=7
- No DLT, max dose tested 1.25 mg/kg




Baseline Characteristics and Demographics


Demographics		N=34
Age	Median, years (range)	40.5 (18-66)
Sex, n (%)	Female	16 (47)
	Male	18 (53)
Race, n (%)	Asian	6 (18)
	Black or African American	2 (6)
	White	16 (47)
	Other	2 (6)
	Not reported	8 (23)
Baseline ATBR during run-in	Mean (range)	54.9 (0, 372.0)
	Median (Q1, Q3)	23.6 (5.5, 59.6)
Cause of bleed (%)	Spontaneous	68
	Traumatic	25
	Iatrogenic	7

Dose-Dependent Increase in Exposure and FVIIa Levels

Sutacimig Exhibits Dose-Dependent PK



PD



- Dose-proportional exposure and PD (n= 30)
- FVIIa elevation in all dose cohorts
- 0.9 mg/kg peak PD approximately double that of 0.3 mg/kg and 0.6 mg/kg cohorts
- 0.3 mg/kg Q1W peak below 0.6 mg/kg cohort with trough levels similar to 0.9 mg/kg cohort

Interim Safety Summary

Median exposure: 2 months (range: 0.03–10.15)

	N (%)
Safety population	34 (100)
Any grade AE (all causality)	26 (77)
AE leading to discontinuation	1 (3)
AE in ≥ 10%	
Headache	6 (18)
Nasopharyngitis	6 (18)
D-dimer elevation	6 (18)
≥ Grade 3 AE (non serious)	5(15)
Dental caries	1 (3)
Iron deficiency anemia	1 (3)
Post procedural hemorrhage	1 (3)
Back pain	1 (3)
SAE	
DVT (Gr 2)	1 (3)
Melena (Gr 3)	1 (3)


- **Majority AEs mild to moderate in severity**
- **No thromboses or discontinuations due to AE in ongoing dose levels**
- **Notable AEs:**
 - DVT (0.9 mg/kg Q2W) on Day 46 at peak exposure (previously reported; patient with multiple potential risk factors, managed outpatient; patient discontinued due to AE)
 - Grade 3 melena Day 2, assessed as unrelated and resolved
 - Grade 3 post-procedural hemorrhage (following dental procedure, resolved with 5 mcg/kg administration of rFVIIa); iron deficiency anemia (D1-3, resolved)
 - D-dimer elevation in 6 participants (all low grade); 1 associated with previously reported DVT; all others associated with treated bleeding events; otherwise asymptomatic; no associated clinical thrombocytopenia (all platelet values > 120), or hypofibrinogenemia
- **4/34 participants developed neutralizing ADA; 2/4 resolved with continued dosing; no associated safety events**

Improvement in Thrombin Generation (Lag Time) Demonstrates TLT-1 Potentiation of FVIIa by Sutacimig

Baseline and post-sutacimig lag time compared to rFVIIa-spiked baseline sample lagtime


- GT patients exhibit extended lag time
- Lag time improvement on sutacimig comparable to improvement in baseline samples spiked with 3 nM to 8 nM rFVIIa
- Mean FVIIa post-sutacimig for these patients was 0.26 nM
- Demonstrates TLT-1 potentiation of FVIIa

Lag time improved ~50% in sutacimig-treated patients, comparable to clinically relevant rFVIIa



Median Annualized Treated Bleed Rate on Weekly or Biweekly Sutacimig

Up to 12 weeks of dosing; median exposure 8.5 weeks; all doses included



Dosing regimen	N
0.3 mg/kg Q2W	11
0.6 mg/kg Q2W	12
0.9 mg/kg Q2W	5
0.3 mg/kg Q1W	5

ATBR	Run-In	Post-sutacimig
Median	21.2	4.6
Interquartile range	4.8-55.6	0-27.4

Clinical Impact of Sutacimig



Participant

37 year-old male with recurrent epistaxis, oral iron intolerance, and anti-GPIIb/IIIa antibodies on sutacimig treatment for 6 months

Cessation of epistaxis-induced transfusions on sutacimig 0.6 mg/kg Q2W



sutacimig

Epistaxis history at baseline – in prior 3 months

- Daily epistaxis lasting >30 minutes
- Transfusions required
- Medical attention needed

6 months post-sutacimig

- Decreased epistaxis frequency
- Transfusion-free for 6 months
- No medical attention needed for 6 months



Participant

50 year-old female with history of rFVIIa use for bleeding; baseline ATBR 46; on sutacimig treatment for 9.5 months

Successful post-procedure hemostasis with reduced rFVIIa sutacimig 0.6 mg/kg Q2W

ATBR reduction 46 → 0

Successful hemostasis post dental procedure using >90% reduced dose of rFVIIa*

90 mcg/kg (typical dose)
→ 5 mcg/kg

Conclusions

- Interim data from N=34 participants with Glanzmann thrombasthenia and baseline ATBR mean/median of 55/24 with 0.03 to 10 months exposure
- No thromboses or discontinuation due to AE in ongoing dose levels; majority of AEs mild or moderate; one DVT at prior 0.9 mg/kg dose level
- Dose-dependent peak PK, PD at ongoing dose levels with demonstration of FVIIa elevation 2-4-fold above baseline and improved thrombin generation (lag time)
- Sutacimig continues to demonstrate clinically meaningful >50% reduction in ATBR
- Safety and clinical activity at ongoing SC weekly or biweekly doses support potential as prophylactic agent in GT

Next steps

- Identification of a Phase 3 dose and regimen following additional treatment and follow-up

Acknowledgement



The authors thank the study participants, their families, the investigators and study site personnel

Investigators: Suthesh Sivapalaratnam, Laurent Frenzel, Frederico Xavier, Peter Verhamme, Paul Sautier, Roger Schutgens, Andrea Artoni, Roseline D'Orion, Keith Gomez, Gillian Lowe, Maissaa Janbain, Jenny Zhou, Rajiv Pruthi, Julie Tarrant, Giancarlo Castaman, Barbara Konkle, Ulrike Lorch, and Matej Goricar

Acknowledgements: Soujanya Sunkaraneni, Ally He, Huy Van Nguyen*

***Sponsor:** Hemab Therapeutics

ENROLLMENT COMPLETE: Glanzmann thrombasthenia

Country	Phase 1/2 sites
Belgium	University Hospital Leuven
France	AP-HP Hôpital Bicêtre
	AP-HP Hôpital Necker
	AP-HM - Hôpital de la Timone
Italy	Careggi University Hospital
	IRCCS Ca' Granda Maggiore Hospital
Netherlands	University Medical Centre Utrecht
United Kingdom	Leeds Teaching Hospitals
	The Royal London Hospital
	Richmond Pharmacology
	Royal Free London
	Queen Elizabeth Hospital Birmingham
United States	University of California, San Diego
	Tulane University Medical Centre
	Mayo Clinic - Rochester
	University of Pittsburgh
	Washington Institute for Coagulation